Peri-orbital Aesthetic Rejuvenation Surgical Protocol and Clinical Outcomes

2017 ◽  
Vol 34 (2) ◽  
pp. 81-91 ◽  
Author(s):  
Robert J. Troell

The aim was to examine the validity of a peri-orbital rejuvenation protocol with clinical surgical results evaluating patient satisfaction and complications. Retrospective patient data and chart review was performed on 367 patients who underwent a blepharoplasty procedure. Outcome measures were dependent upon direct patient responses on postoperative visits, photographic documentation, and physical examination findings. The other outcome measure was termed a successful surgical outcome. This definition included the procedure goal was met, no postoperative complication was observed, there was no need for a revision, and the patient was satisfied with the outcome. From a cosmetic result standpoint, 99.5% (365 of 367 patients) were satisfied with the outcome. There were a total of 456 blepharoplasty surgeries: 203 upper, 75 lower, and 89 quad blepharoplasties. The patients defined with a successful outcome totaled 94.0% (345 of 367 patients). There was a complication incidence of 2.5%. Revision surgery occurred in 3% of upper blepharoplasties and in 1.8% of lower blepharoplasties. Adjuvant procedures performed either at the same time or as a staged procedure to complete the peri-orbital rejuvenation protocol were as follows: browlift surgery 24, brow or hairline dermal filler placement 4, facial silastic implant surgery 9, mid-facelift 16, lateral canthopexy 7, facelift 41, laser skin resurfacing 53, trichloroacetic acid peels 19, radiofrequency skin treatments 19, lower eyelid fat transposition 10, and facial fat transfer 25. The peri-orbital rejuvenation surgical protocol, surgical blepharoplasty techniques, and adjuvant procedure techniques performed revealed a high benefit to risk profile and high patient satisfaction rate.

Author(s):  
Ravindra Bharathi ◽  
Praveen Bhardwaj ◽  
Vigneswaran Varadharajan ◽  
Hari Venkatramani ◽  
S Raja Sabapathy

AbstractReplantation of digital amputations is now the accepted standard of care. However, rarely will a replantation surgeon be presented with amputated fingers which have been previously replanted. In our literature search, we could find only one publication where a replanted thumb suffered amputation and was successfully replanted again. We report the technical challenges and the outcome of replanting two fingers which suffered amputation 40 months after the initial replantation and were successfully replanted again. Replantation was critical since the amputated fingers were the only two complete fingers in that hand which had initially suffered a four-finger amputation. The second-time replantation of previously replanted fingers is reported to allay the concern of the reconstructive surgeon when faced with this unique situation of “repeat amputation of the replanted finger.” Second-time replantation is feasible and is associated with high-patient satisfaction. Replantation must be attempted especially in the event of multiple digit amputations.


2016 ◽  
Vol 17 (1) ◽  
Author(s):  
Petter Morten Pettersen ◽  
Joakim Eriksson ◽  
Hallgeir Bratberg ◽  
Lars Eldar Myrseth ◽  
Lise Grete Bjørnstad ◽  
...  

2007 ◽  
Vol 63 (1) ◽  
pp. 94-95 ◽  
Author(s):  
Ninaad S. Awsare ◽  
James A. Green ◽  
Beverley Aldwinckle ◽  
Damian C. Hanbury ◽  
Greg B. Boustead ◽  
...  

2014 ◽  
Vol 04 (11) ◽  
pp. 263-275
Author(s):  
Ulrike Reuter ◽  
Babette Jurack ◽  
Nils Engelmann ◽  
Thilo Busch ◽  
Joerg Schnoor

Author(s):  
Lily N. Trinh ◽  
Sarah E. Grond ◽  
Amar Gupta

AbstractThere is significant variation in treatment parameters when treating the infraorbital region. Thorough knowledge of these pertinent factors, choice of the optimal filling material, and proper understanding of the anatomy of this unforgiving region will contribute to a safe, effective, and natural result. We aim to conduct a systematic review of published literature related to soft tissue fillers of the tear trough and infraorbital region. A search of published literature was conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and included PubMed, Embase, and Science Direct databases. The Medical Subject Headings (MeSH) terms used were “tear trough” OR “infraorbital” AND “dermal filler” OR “hyaluronic acid” OR “poly-L-lactic acid” OR “calcium hydroxyapatite” OR “Restylane” OR “Radiesse” OR “Perlane” OR “Juvéderm” OR “Belotero.” Different combinations of these key terms were used. The initial search identified 526 articles. Six additional articles were identified through references. Two-hundred twenty-five duplicates were removed. A total of 307 studies were screened by title and abstract and 258 studies were eliminated based on inclusion and exclusion criteria. Forty-nine articles underwent full-text review. The final analysis included 23 articles. Patient satisfaction was high, and duration of effect ranged from 8 to 12 months. Restylane was most commonly used. Injection technique varied, but generally involved placing filler pre-periosteally, deep to orbicularis oculi muscle, anterior to the inferior orbital rim via serial puncture or retrograde linear threading with a 30-gauge needle. Topical anesthetic was most commonly used. Side effects were generally mild and included bruising, edema, blue–gray dyschromia, and contour irregularities. Nonsurgical correction of the tear trough deformity with soft tissue filler is a minimally invasive procedure with excellent patient satisfaction with long-lasting effects. It is essential to have a fundamental understanding of the relevant anatomy and ideal injection technique to provide excellent patient outcomes and prevent serious complications.


2007 ◽  
Vol 17 (5_suppl) ◽  
pp. 28-30 ◽  
Author(s):  
C. Migdal

Several fixed combination products are now available in glaucoma management. Considerations when selecting combination therapy include safety, finding the best combination of mechanisms of action. Combigan® is one such product that has been shown to be more effective than either of its constituent agents, brimonidine or timolol, used alone. It has at least a similar intraocular pressure (IOP)-lowering effect as the concomitant use of its two constituents, and it produces a significant additional lowering of IOP in patients who switch from other therapies, including Cosopt®. Combigan has high patient satisfaction ratings.


Sign in / Sign up

Export Citation Format

Share Document